about
Available and emerging treatments for Parkinson's disease: a reviewLevodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable FeaturesPharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesQuantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study.Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study.The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian ratsImpact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian ratsDeep brain stimulation in Parkinson's diseaseMitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistPresynaptic effects of levodopa and their possible role in dyskinesia.A microfluidic-based neurotoxin concentration gradient for the generation of an in vitro model of Parkinson's diseasePathological basal ganglia activity in movement disorders.Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.Clinical aspects and management of levodopa-induced dyskinesia.Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian StriatumAnti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsAltered Neuronal Firing Pattern of the Basal Ganglia Nucleus Plays a Role in Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease.A survey of impulse control disorders in Parkinson's disease patients in Shanghai area and literature review.Current approaches to the treatment of Parkinson's diseaseLevodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsCell-based assays for Parkinson's disease using differentiated human LUHMES cells.Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management.Optogenetics and its application in neural degeneration and regeneration.Excessive Sensitivity to Uncertain Visual Input in L-DOPA-Induced Dyskinesias in Parkinson's Disease: Further Implications for Cerebellar Involvement.Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis.Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.Continuous buccolingual masticatory dyskinesia in Parkinson's disease.Dysregulation of BET proteins in levodopa-induced dyskinesia.PBF509, an Adenosine A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
P2860
Q24633444-6208E9C4-8B43-44EE-8D32-E95D37C4CAF8Q24647141-A91FF7F3-AC13-4B6B-BC85-C7B7A5B5DF30Q26752602-A39E6D40-C372-4255-8751-FE8B518A579CQ27021464-AE0B1126-33F4-470B-894F-270E9BE5FEBCQ28082230-546B1E65-A39A-484C-886C-C5DDD33CC800Q28088705-1E373E55-9F79-46D3-8AB6-DA7623EB9646Q33400886-7C12BD52-A65A-4308-8A3B-8D2C1D7E9616Q33652773-D38200A7-209A-4D3E-B87D-DFA8CCB669EAQ33917293-6E50E674-75DE-43EE-ABD0-57728D92C1E1Q33917299-458F30A3-A310-426F-9DC6-1A9200A432FEQ34131256-CFAFDCF8-0120-4226-875D-8188CFEBDAD5Q34255809-77570331-D925-4CE9-A3B2-A0B0FB1F65C7Q34460675-85A4D559-9FDC-4406-8AF9-A4836861A494Q34492283-9EAE63BB-82FF-4D28-A56E-733D6BE598AAQ34504316-9A92B0E4-44A6-41BC-B9B8-340F12827046Q35040280-A9B2DA6E-93EA-436E-8FAF-C0916DED3631Q35132663-7E351AFD-C73D-413F-B625-48C772036BC9Q35532146-3F33F901-7BFF-48FA-B7B7-4EB2840B89CEQ35828317-3415F794-1A15-43C4-B8D4-C5E01FCA04D8Q36022700-D9F2A751-9503-4F5F-88C1-283740A3AECEQ36034592-05BEF1F3-12E8-4954-BAFA-C9C7125E2ABAQ36248857-DD9212E3-43FE-4376-9813-F0E4DCCDBE8DQ36251899-B4A8656D-ADA0-43FF-8435-A7F531779740Q36316264-3B99076B-F5C1-4FEA-8A98-D6AFE8956A66Q36591916-BD3A8E77-3850-4DDB-9E12-9ACE878BFF78Q36876438-B6168B4F-431F-4003-A9F2-2AE51E6F08EEQ38156760-1E1F5CDC-E5E5-42CC-94DF-B0B82EC5E0C5Q38978672-F8289A9E-4457-4B53-A078-C4C64DF006B5Q41626118-5DABB8E7-0AC5-4813-8530-AADF1443CBA5Q41667414-45A29C01-DD30-403F-B99D-4261E3926C17Q41910371-52AB8476-48BF-47C1-A575-F0348E125D73Q42127267-B33534D8-458C-4EEA-87F6-4F589D66E41AQ42183668-91A20500-7227-4005-94F0-1ACD5FA8FEF4Q42372900-F4F02101-F025-46DE-9F94-340F6A07CAB6Q47114857-16257E2B-8AA2-40C5-978B-7547008D2A4BQ50592833-818FD48D-59AD-4C4F-96C0-2937884A4709Q58587583-2A05D2A7-E360-4DA9-901D-4F9610151092
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The spectrum of levodopa-induced dyskinesias.
@ast
The spectrum of levodopa-induced dyskinesias.
@en
type
label
The spectrum of levodopa-induced dyskinesias.
@ast
The spectrum of levodopa-induced dyskinesias.
@en
prefLabel
The spectrum of levodopa-induced dyskinesias.
@ast
The spectrum of levodopa-induced dyskinesias.
@en
P1433
P1476
The spectrum of levodopa-induced dyskinesias.
@en
P304
S2-9; discussion S9-11
P433
P50
P577
2000-04-01T00:00:00Z